| [1] |
Harbeck N, Gluz O, Clemens MR, et al. Prospective WSG phase ⅢPlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediateto-high genomic risk HER2-negative, early breast cancer [EB/OL].[2017-08-20]. http:/ /ascopubs. org/doi/abs/10. 1200/JCO. 2017.35.15_suppl.504.
|
| [2] |
Blum JL,Flynn PJ,Yothers G,et al. Interim joint analysis of the ABC(anthracyclines in early breast cancer) phase Ⅲtrials (USOR 06-090,NSABP B-46I/USOR 07132, NSABP B-49 [ NRG Oncology])comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxanebased chemotherapy regimens (TaxAC) in women with high-risk,HER2-negative breast cancer [EB/OL]. [2017-08-20]. http:/ /ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.1000.
|
| [3] |
van Ramshorst MS, van Werkhoven E, Mandjes IA, et al. A phase Ⅲtrial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2 + breast cancer: The TRAIN-2 study (BOOG 2012-03) [EB/OL]. [2017-08-20]. http:/ /ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.507.
|
| [4] |
Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer[J]. Cochrane Database Syst Rev,2012, (4):CD006243.
|
| [5] |
Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer[J]. N Engl J Med,2015,372(8):724-734.
|
| [6] |
Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study[J]. J Clin Oncol,2012,30(21):2585-2592.
|
| [7] |
Von Minckwitz G,Procter MJ,De Azambuja E,et al. APHINITY trial(BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients(pts) with HER2-positive early breast cancer (EBC) [EB/OL].[2017-08-20]. http:/ /ascopubs. org/doi/abs/10. 1200/JCO. 2017.35.18_suppl.LBA500.
|
| [8] |
Moreno-Aspitia A, Holmes EM, Jackisch C , et al. Updated results from the phase Ⅲ ALTTO trial (BIG 2-06; NCCTG (Alliance)N063D) comparing one year of anti-HER2 therapy with lapatinib alone(L), trastuzumab alone (T), their sequence (T →L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer [EB/OL]. [2017-08-20]. http:/ /ascopubs. org/doi/abs/10.1200/JCO.2017.35.15_suppl.502.
|
| [9] |
Piccart-Gebhart MJ, Holmes AP, Baselga J, et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D)comparing one year of anti-HER2 therapy with lapatinib alone (L),trastuzumab alone (T), their sequence (T→L), or their combination(T+L) in the adjuvant treatment of HER2-positive early breast cancer(EBC) [EB/OL]. [2017-08-20]. http:/ /ascopubs.org/doi/abs/10.1200/jco.2014.32.18_suppl.lba4.
|
| [10] |
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer(HERA): an open-label, randomised controlled trial[J]. Lancet,2013,382(9897):1021-1028.
|
| [11] |
Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial[J]. Lancet Oncol,2013,14(8):741-748.
|
| [12] |
Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer[J]. N Engl J Med,2006,354(8):809-820.
|
| [13] |
Conte PF, Bisagni G, Frassoldati A, et al. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase Ⅲmulticentric Italian study Short-HER [EB/OL]. [2017-08-20].http:/ /ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.501.
|
| [14] |
Davies C, Pan H, Godwin J, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet,2013,381(9869):805-816.
|
| [15] |
Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years[J]. N Engl J Med, 2016, 375(3):209-219.
|
| [16] |
Colleoni M, Luo W, Karlsson P, et al. SOLE (Study of Letrozole Extension): A phase Ⅲrandomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC) [EB/OL]. [2017-08-20]. http:/ /ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.503.
|
| [17] |
Bartlett J, Kalatskaya I, Yousif F, et al. Targeted sequencing in a phase III trial of luminal breast cancer: Identification of novel targets[EB/OL]. [2017-08-20]. http:/ /ascopubs. org/doi/abs/10. 1200/JCO.2017.35.15_suppl.505.
|
| [18] |
Adams S, Schmid P, Rugo HS, et al. Phase 2 study of pembrolizumab(pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A[EB/OL]. [2017-08-20]. http:/ /ascopubs. org/doi/abs/10. 1200/JCO. 2017. 35. 15_suppl.1008.
|
| [19] |
Nanda R, Liu MC, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from ISPY 2[EB/OL]. [2017-08-20]. http:/ /ascopubs. org/doi/abs/10.1200/JCO.2017.35.15_suppl.506.
|
| [20] |
Morrow M, Katz SJ, Jagsi R. Mastectomy rates in relation to adoption of a margin guideline[EB/OL]. [2017-08-20]. http:/ /ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.508.
|